Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors.
Sign Up to like & getrecommendations! Published in 2018 at "Drug discovery today"
DOI: 10.1016/j.drudis.2017.10.004
Abstract: Epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, show excellent clinical efficacy for patients with non-small cell lung cancer (NSCLC) with EGFR mutations, including Exon 19 deletion and single-point substitution,… read more here.
Keywords: kinase inhibitors; egfr; egfr tkis; egfr tyrosine ... See more keywords
Sulfonylated Indeno[1,2-c]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors
Sign Up to like & getrecommendations! Published in 2023 at "ACS Omega"
DOI: 10.1021/acsomega.3c01195
Abstract: The epidermal growth factor receptor (EGFR) has been considered a potential target for lung cancer therapy due to its essential role in regulating the survival and proliferation of cancer cells. Although erlotinib, a potent EGFR… read more here.
Keywords: sulfonylated indeno; potent egfr; tyrosine kinase; egfr ... See more keywords
Comparison of therapeutic effects of EGFR‐tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function
Sign Up to like & getrecommendations! Published in 2018 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.12568
Abstract: We compared the therapeutic effect of EGFR‐tyrosine kinase inhibitors (TKIs) on 19Del and L858R mutations in advanced lung adenocarcinoma on cellular immune function and explored the factors influencing the curative effect and prognosis. read more here.
Keywords: kinase inhibitors; effect; egfr tyrosine; 19del l858r ... See more keywords
Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.12779
Abstract: Although patients with EGFR‐mutant non‐small‐cell lung cancer (NSCLC) benefit from treatment with EGFR‐tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired resistance. We conducted a retrospective study to evaluate the efficacy… read more here.
Keywords: cell lung; egfr tyrosine; non small; small cell ... See more keywords
Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
Sign Up to like & getrecommendations! Published in 2018 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.12847
Abstract: The standard of care for fit locally advanced non‐small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA‐mEGFR), the role of EGFR‐tyrosine… read more here.
Keywords: concurrent chemoradiotherapy; lung adenocarcinoma; kinase inhibitors; mutant egfr ... See more keywords
Identification of 20(S)-Ginsenoside Rh2 as a Potential EGFR Tyrosine Kinase Inhibitor
Sign Up to like & getrecommendations! Published in 2022 at "Oxidative Medicine and Cellular Longevity"
DOI: 10.1155/2022/6119737
Abstract: As the main active ingredients of Panax ginseng, ginsenosides possess numerous bioactivities. Epidermal growth factor receptor (EGFR) was widely used as a valid target in anticancer therapy. Herein, the EGFR targeting activities of 20(S)-ginsenoside Rh2… read more here.
Keywords: kinase; potential egfr; tyrosine kinase; egfr ... See more keywords
Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors: A perspective study in NSCLC patients using targeted next generation sequencing.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20576
Abstract: e20576Background:Patients with non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kina... read more here.
Keywords: novel resistance; generation; resistance mechanisms; egfr tyrosine ... See more keywords
The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21237
Abstract: e21237Background: Non-small cell lung cancer (NSCLC) with activating EGFR mutations in exon 19 or 21 usually responds to EGFR tyrosine kinase inhibitors (TKIs), but sometimes the responses can only... read more here.
Keywords: non small; cell lung; egfr tyrosine; lung cancer ... See more keywords
Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase
Sign Up to like & getrecommendations! Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0217031
Abstract: EGFR (epidermal growth factor receptor) plays the critical roles in the vital cell activities, proliferation, differentiation, migration and survival in response to polypeptide growth factor ligands. Aberrant activation of this receptor has been demonstrated in… read more here.
Keywords: substrate binding; binding site; peptide substrate; egfr tyrosine ... See more keywords
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2021.570921
Abstract: EGFR tyrosine kinase inhibitors (TKIs) are the front-line treatment in EGFR mutation positive advanced non-small cell lung cancer (aNSCLC) patients. Generally, they are well-tolerated but skin toxicity is common (45–100% of patients) and may adversely… read more here.
Keywords: cell lung; report; egfr tyrosine; non small ... See more keywords
Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12051283
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinases inhibitors (TKIs) are effective therapies for non-small cell lung cancer (NSCLC) patients whose tumors harbor an EGFR activating mutation. However, this treatment is not curative due to primary… read more here.
Keywords: inhibitor; fatty acid; t790m; egfr tyrosine ... See more keywords